An atherogenic paigen-diet aggravates nephropathy in type 2 diabetic OLETF rats

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Nozako, Masanori ^a   Koyama, Takashi ^a   Nagano, Chifumi ^a   Sato, Makoto ^a   Matsumoto, Satoshi ^a   Mitani, Kiminobu ^a   Yasufuku, Reiko ^a   Kohashi, Masayuki ^a   Yoshikawa, Tomohiro ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BINDING PROTEIN; CHOLESTEROL; FATTY ACID; GLUCOSE; KIDNEY INJURY MOLECULE 1; LIVER FATTY ACID BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE EXACERBATION; FATTY ACID BLOOD LEVEL; GLOMERULUS; GLUCOSE BLOOD LEVEL; KIDNEY HYPERTROPHY; KIDNEY TUBULE DAMAGE; LIPID STORAGE; MACROPHAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIGEN DIET; RAT; URINARY EXCRETION; ADVERSE EFFECTS; ANIMAL; BLOOD; BLOOD PRESSURE; COMPLICATION; DIABETIC NEPHROPATHIES; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE; METABOLISM; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOLOGY; TIME FACTOR;

ANIMALS; BIOMARKERS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; KIDNEY TUBULES; LIPOPROTEINS; MALE; RATS; RATS, INBRED OLETF; RNA, MESSENGER; TIME FACTORS;

EID: 84955602380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143979     Document Type: Article

References (52)

1. Martini S, Eichinger F, Nair V, Kretzler M. Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord 2008; 9: 267-274. doi: 10.1007/s11154-008-9103-3 PMID: 18704688
2. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004; 34: 785-796. PMID: 15606719
3. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454. doi: 10.2337/db08-0057 PMID: 18511445
4. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340. doi: 10.1038/nrneph.2011.51 PMID: 21537349
5. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012; 30: 49-59. doi: 10.1111/j.1755-5922.2010.00218.x PMID: 20718759
6. Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res 2013; 2013: 248563. doi: 10.1155/2013/248563 PMID: 23862164
7. Mulec H, Johnsen SA, Wiklund O, Björck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993; 22: 196-201. PMID: 8322783
8. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994; 45: S125-131. PMID: 8158881
9. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998-1004. PMID: 9588433
10. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26: 1402-1407. PMID: 12716796
11. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010; 17: 4256-4269. PMID: 20939814
12. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 2013; 17: 20-33. doi: 10.1016/j.cmet.2012.11.012 PMID: 23312281
13. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 2013; 9: 99-111. doi: 10.1038/nrneph.2012.279 PMID: 23247571
14. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-1428. PMID: 1397718
15. Kawano K, Mori S, Hirashima T, Man ZW, Natori T. Examination of the pathogenesis of diabetic nephropathy in OLETF rats. J Vet Med Sci 1999; 61: 1219-1228. PMID: 10593580
16. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985; 57: 65-73. PMID: 3841001
17. Getz GS, Reardon CA. Diet and murine atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 242-249. PMID: 16373607
18. Yoshida M, Kimura H, Kyuki K, Ito M. Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet. Eur J Pharmacol 2006; 548: 174-180. PMID: 16979162
19. Niimi M, Keyamura Y, Nozako M, Koyama T, Kohashi M, Yasufuku R, et al. Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. Lipids Health Dis 2013; 12: 166. doi: 10.1186/1476- 511X-12-166 PMID: 24188322
20. Shimada M, Ishibashi S, Inaba T, Yagyu H, Harada K, Osuga JI, et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci U S A 1996; 93: 7242-7246. PMID: 8692976
21. Yoshikawa T, Shimano H, Chen Z, Ishibashi S, Yamada N. Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice. Horm Metab Res 2001; 33: 472-479. PMID: 11544561
22. Rajendran S, Deepalakshmi PD, Parasakthy K, Devaraj H, Devaraj SN. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996; 123: 235-241. PMID: 8782854
23. Moore E, Bellomo R, Nichol A. Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. Minerva Anestesiol 2010; 76: 425-440. PMID: 20473256
24. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int 2008; 73: 1008-1016. PMID: 18094679
25. Patrakka J, Tryggvason K. Nephrin - a unique structural and signaling protein of the kidney filter. Trends Mol Med 2007; 13: 396-403. PMID: 17766183
26. Okuno S, Kondo M, Yamasaki Y, Miyao H, Ono T, Iwanaga T, et al. Substitution of Dmo1 with normal alleles results in decreased manifestation of diabetes in OLETF rats. Diabetes Obes Metab 2002; 4: 309-318. PMID: 12190994
27. Yamada T, Kose H, Ohta T, Matsumoto K. Genetic dissection of complex genetic factor involved in NIDDM of OLETF rat. Exp Diabetes Res 2012; 2012: 582546. doi: 10.1155/2012/582546 PMID: 23118743
28. Moran TH. Unraveling the obesity of OLETF rats. Physiol Behav 2008; 94: 71-78. doi: 10.1016/j. physbeh.2007.11.035 PMID: 18190934
29. Miyamoto S, Shikata K, Miyasaka K, Okada S, SasakiM, Kodera R, et al. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes 2012; 61: 897-907. doi: 10.2337/db11-0402 PMID: 22357963
30. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16: 703-711. PMID: 15647337
31. Koike T, Tomoda F, Kinuno H, Inoue H, Takata M. Abnormal renal structural alterations during the development of diabetes mellitus in Otsuka Long-Evans Tokushima Fatty rats. Acta Physiol Scand 2005; 184: 73-81. PMID: 15847646
32. Hashimoto S, Yamada K, Kawata T, Mochizuki T, Schnermann J, Koike T. Abnormal autoregulation and tubuloglomerular feedback in prediabetic and diabetic OLETF rats. Am J Physiol Renal Physiol 2009; 296: F598-604. doi: 10.1152/ajprenal.00074.2008 PMID: 19106213
33. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-3108. PMID: 11748108
34. Desai MS, Mariscalco MM, Tawil A, Vallejo JG, Smith CW. Atherogenic diet-induced hepatitis is partially dependent on murine TLR4. J Leukoc Biol 2008; 83: 1336-1344. doi: 10.1189/jlb.0607390 PMID: 18334542
35. Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis 2011; 21:79-85. doi: 10.1016/j.numecd.2010.10.002 PMID: 21186102
36. Ichikawa D, Kamijo-Ikemori A, Sugaya T, Shibagaki Y, Yasuda T, Katayama K, et al. Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation. Am J Physiol Renal Physiol 2014; 306: F655-663. doi: 10.1152/ajprenal. 00460.2013 PMID: 24431207
37. Lin Q, Chen Y, Lv J, Zhang H, Tang J, Gunaratnam L, et al. Kidney injury molecule-1 expression in IgA nephropathy and its correlation with hypoxia and tubulointerstitial inflammation. Am J Physiol Renal Physiol 2014; 306: F885-895. doi: 10.1152/ajprenal.00331.2013 PMID: 24523388
38. Humphreys BD, Xu F, Sabbisetti V, Grgic I, Naini SM, Wang N, et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123: 4023-4035. doi: 10.1172/JCI45361 PMID: 23979159
39. Nicholas SB, Liu J, Kim J, Ren Y, Collins AR, Nguyen L, et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2010; 77: 588-600. doi: 10.1038/ki.2009.518 PMID: 20130530
40. Tachibana H, Ogawa D, Matsushita Y, Bruemmer D, Wada J, Teshigawara S, et al. Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J Am Soc Nephrol 2012; 23: 1835-1846. doi: 10.1681/ASN.2012010022 PMID: 23085633
41. Qin P, Borges-Marcucci LA, Evans MJ, Harnish DC. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes. Am J Physiol Gastrointest Liver Physiol 2005; 289: G267-273. PMID: 15817812
42. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049. PMID: 17767165
43. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Nakao K. Macrophage-mediated glucolipotoxicity via myeloid-related protein 8/toll-like receptor 4 signaling in diabetic nephropathy. Clin Exp Nephrol 2014; 18: 584-592. doi: 10.1007/s10157-013-0922-5 PMID: 24357461
44. Kuwabara T, Mori K, Kasahara M, Yokoi H, Imamaki H, Ishii A, et al. Predictive significance of kidney myeloid-related protein 8 expression in patients with obesity- or type 2 diabetes-associated kidney diseases. PLoS One 2014; 9: e88942. doi: 10.1371/journal.pone.0088942 PMID: 24558454
45. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456. PMID: 9811921
46. Kees-Folts D, Sadow JL, Schreiner GF. Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 1994; 45: 1697-1709. PMID: 7933818
47. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hase H, Kaneko T, et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002; 62: 1628-1637. PMID: 12371963
48. Wang G, Gong Y, Anderson J, Sun D, Minuk G, Roberts MS, et al. Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology 2005; 42: 871-879. PMID: 16175609
49. Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol 2009; 20: 1877-1887. doi: 10.1681/ASN.2008070804 PMID: 19118148
50. Gorin Y, Wauquier F. Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease. Mol Cells 2015; 38: 285-296. doi: 10.14348/molcells. 2015.0010 PMID: 25824546
51. Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, Górriz JL, Martínez-Castelao A, Navarro- González JF. Diabetic kidney disease: from physiology to therapeutics. J Physiol 2014; 592: 3997-4012. doi: 10.1113/jphysiol.2014.272328 PMID: 24907306
52. Martínez-Castelao A, Navarro-González JF, Górriz JL, de Alvaro F. The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years. J Clin Med 2015; 4: 1207-1216. doi: 10.3390/jcm4061207 PMID: 26239554